Disc Medicine (IRON) EBT (2020 - 2026)
Disc Medicine (IRON) posted quarterly EBT of -$59.5 million for Q2 2026, down 7.73% year-over-year from -$64.4 million in Q2 2025, and up 6.29% quarter-over-quarter from -$63.5 million in Q1 2026.
Disc Medicine (IRON) EBT (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported EBT for 7 consecutive years, with -$59.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT fell 7.73% year-over-year to -$59.5 million; the TTM figure through Jun 2026 stood at -$245.9 million (down 69.68% YoY), while the FY2025 annual figure was -$212.2 million, down 94.63% from the prior year.
- EBT improved to -$59.5 million in Q2 2026 per IRON's latest filing, from -$63.5 million in the prior quarter.
- Across five years, EBT topped out at -$9.6 million in Q2 2022 and bottomed at -$63.5 million in Q1 2026.
- Historically, EBT has averaged -$31.5 million across 5 years, with a median of -$26.4 million in 2024.
- On a YoY basis, EBT climbed as much as 46.27% in 2022 and fell as far as 155.29% in 2022.
- Disc Medicine's EBT stood at -$11.2 million in 2022, then plunged by 109.42% to -$23.5 million in 2023, then retreated by 24.35% to -$29.3 million in 2024, then sank by 107.55% to -$60.8 million in 2025, then climbed by 2.15% to -$59.5 million in 2026.
- Business Quant data shows IRON's EBT at -$59.5 million in Q2 2026, -$63.5 million in Q1 2026, and -$60.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Disc Medicine | 3.02 Bn | 3.02 Bn | - | -59.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.46 Mn |
| Mar 31, 2026 | -63.45 Mn |
| Dec 31, 2025 | -60.44 Mn |
| Sep 30, 2025 | -62.22 Mn |
| Jun 30, 2025 | -55.20 Mn |
| Mar 31, 2025 | -33.97 Mn |
| Dec 31, 2024 | -29.28 Mn |
| Sep 30, 2024 | -26.49 Mn |
| Jun 30, 2024 | -26.29 Mn |
| Mar 31, 2024 | -26.94 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -14.10 Mn |
| Jun 30, 2023 | -15.92 Mn |
| Mar 31, 2023 | -22.76 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 20.34 Mn |
| Sep 30, 2021 | -18.55 Mn |